Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life
Objective: To evaluate the relationship between non-motor symptom (NMS) severity, quality of life (QoL), and activities of daily living (ADL) in advanced Parkinson’s disease (PD)…The effect of early STN-DBS in PD patients on axial symptoms: a 2-year randomized controlled trial (EARLYSTIM-Gait analysis)
Objective: This study assesses the effect of STN-DBS in early PD patients on axial symptoms compared to BMT. Background: In well-selected candidates, STN-DBS offers symptom…Efficacy and Safety of Therapeutic Interventions to Treat Motor Symptoms in Late Stage Parkinson’s Disease: A Systematic Review
Objective: Evaluate the efficacy and safety of therapeutic interventions to treat the motor symptoms in late stage PD. Background: PD patients in late stage are…Understanding neural activation in semantic fluency in Parkinson’s disease with mild cognitive impairment
Objective: To identify neural mechanisms relating to semantic fluency deficits in PD-MCI and to establish possible neuroimaging markers for Parkinson’s disease (PD) with dementia. Background:…Morphometric changes in Parkinson’s disease manifesting freezing of gait
Objective: To study structural Gray Matter (GM) and White Matter (WM) changes in Parkinson’s Disease (PD) patients with Freezing of Gait (FOG). Background: FOG is…The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.
Objective: To evaluate MIBG and DAT SPECT for the diagnosis of Parkinson’s disease (PD) and related disorders, we performed 123I-meta-iodobenzylguanzylguanidine (MIBG) myocardial scintigraphy and (123I)-FP-CIT…Brain structural and functional changes associated with frequent falls in Parkinson’s disease
Objective: We investigated brain structural and functional changes associated with falls. Background: Gait and balance disorders are one of the common clinical features of Parkinson’s…Signal intensity of cerebral gyri in corticobasal degeneration on phase difference enhanced MR images: Comparison with progressive supranuclear palsy and Parkinson’s disease
Objective: We evaluated the signal intensity of the cerebral gyri (CG) on phase difference enhanced imaging (PADRE) for the patients with corticobasal degeneration (CBD), progressive…The prevalence of cerebral microbleeds in patients with Parkinson’s disease and multiple system atrophy
Objective: Here, we compared the prevalence of cerebral microbleeds (CMBs) in patients with parkinsonian disorders, including Parkinson’s diseaseParkinson’s disease (PD) and multiple system atrophy (MSA).…Evaluation of SV2A expression with [18F]MNI-944 PET imaging in healthy controls (HC) and Parkinson disease (PD)
Objective: To evaluate [18F]MNI-944, a highly selective synaptic SV2A PET imaging tracer, as a biomarker for longitudinal studies in early PD. Background: PD symptoms manifest…
- « Previous Page
- 1
- …
- 121
- 122
- 123
- 124
- 125
- …
- 155
- Next Page »